SAFETY DATA SHEET

Ertugliflozin (< 5%) / Sitagliptin Formulation

Version 2.1  Revision Date: 2020/09/28  SDS Number: 2400317-00007  Date of last issue: 2020/03/23
Date of first issue: 2018/02/01

1. PRODUCT AND COMPANY IDENTIFICATION

Chemical product name: Ertugliflozin (< 5%) / Sitagliptin Formulation

Supplier’s company name, address and phone number
Company name of supplier: MSD
Address: Kumagaya, Saitama Prefecture , Xicheng 810 MSD Co., Ltd.
Menuma factory
Telephone: 048-588-8411
E-mail address: EHSDATASTEWARD@msd.com
Emergency telephone number: 1-908-423-6000

Recommended use of the chemical and restrictions on use
Recommended use: Pharmaceutical

2. HAZARDS IDENTIFICATION

GHS classification of chemical product
Skin corrosion/irritation: Category 2
Serious eye damage/eye irritation: Category 1
Short-term (acute) aquatic hazard: Category 3

GHS label elements
Hazard pictograms:

Signal word: Danger

Hazard statements: H315 Causes skin irritation.
H318 Causes serious eye damage.
H402 Harmful to aquatic life.

Precautionary statements:
Prevention:
P264 Wash skin thoroughly after handling.
P273 Avoid release to the environment.
P280 Wear protective gloves/ eye protection/ face protection.

Response:
P302 + P352 IF ON SKIN: Wash with plenty of water.
P305 + P351 + P338 + P310 IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present
and easy to do. Continue rinsing. Immediately call a POISON CENTER/doctor.
P332 + P313 If skin irritation occurs: Get medical advice/attention.
P362 + P364 Take off contaminated clothing and wash it before reuse.

Disposal:
P501 Dispose of contents/container to an approved waste disposal plant.

Other hazards which do not result in classification
Important symptoms and outlines of the emergency assumed:
May form explosive dust-air mixture during processing, handling or other means.

3. COMPOSITION/INFORMATION ON INGREDIENTS

<table>
<thead>
<tr>
<th>Substance / Mixture</th>
<th>Components</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sitagliptin</td>
<td>Chemical name</td>
</tr>
<tr>
<td></td>
<td>Sitagliptin</td>
</tr>
<tr>
<td></td>
<td>Cellulose</td>
</tr>
<tr>
<td></td>
<td>Ertugliflozin</td>
</tr>
<tr>
<td></td>
<td>Magnesium stearate</td>
</tr>
</tbody>
</table>

4. FIRST AID MEASURES

General advice:
In the case of accident or if you feel unwell, seek medical advice immediately. When symptoms persist or in all cases of doubt seek medical advice.

If inhaled:
If inhaled, remove to fresh air.
Get medical attention if symptoms occur.

In case of skin contact:
In case of contact, immediately flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes.
Get medical attention.
Wash clothing before reuse.
Thoroughly clean shoes before reuse.

In case of eye contact:
In case of contact, immediately flush eyes with plenty of water for at least 15 minutes.
If easy to do, remove contact lens, if worn.
Get medical attention immediately.

If swallowed:
If swallowed, DO NOT induce vomiting.
Get medical attention if symptoms occur.
Rinse mouth thoroughly with water.

Most important symptoms and effects, both acute and delayed:
Causes skin irritation.
Causes serious eye damage.
Protection of first-aiders: First Aid responders should pay attention to self-protection, and use the recommended personal protective equipment when the potential for exposure exists (see section 8).

Notes to physician: Treat symptomatically and supportively.

5. FIREFIGHTING MEASURES

Suitable extinguishing media:
- Water spray
- Alcohol-resistant foam
- Carbon dioxide (CO2)
- Dry chemical

Unsuitable extinguishing media: None known.

Specific hazards during firefighting: Avoid generating dust; fine dust dispersed in air in sufficient concentrations, and in the presence of an ignition source is a potential dust explosion hazard. Exposure to combustion products may be a hazard to health.

Hazardous combustion products:
- Carbon oxides
- Metal oxides
- Oxides of phosphorus

Specific extinguishing methods: Use extinguishing measures that are appropriate to local circumstances and the surrounding environment. Use water spray to cool unopened containers. Remove undamaged containers from fire area if it is safe to do so. Evacuate area.

Special protective equipment for firefighters: In the event of fire, wear self-contained breathing apparatus. Use personal protective equipment.

6. ACCIDENTAL RELEASE MEASURES

Personal precautions, protective equipment and emergency procedures: Use personal protective equipment. Follow safe handling advice (see section 7) and personal protective equipment recommendations (see section 8).

Environmental precautions: Avoid release to the environment. Prevent further leakage or spillage if safe to do so. Retain and dispose of contaminated wash water. Local authorities should be advised if significant spillages cannot be contained.

Methods and materials for containment and cleaning up: Sweep up or vacuum up spillage and collect in suitable container for disposal. Avoid dispersal of dust in the air (i.e., clearing dust surfaces with compressed air). Dust deposits should not be allowed to accumulate on surfaces, as these may form an explosive mixture if they are released into the atmosphere in sufficient concentration. Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to determine which regulations are applicable. Sections 13 and 15 of this SDS provide information regarding
7. HANDLING AND STORAGE

Handling

Technical measures: Static electricity may accumulate and ignite suspended dust causing an explosion.

Provide adequate precautions, such as electrical grounding and bonding, or inert atmospheres.

Local/Total ventilation: Use only with adequate ventilation.

Advice on safe handling:

Do not get on skin or clothing.

Do not breathe dust.

Do not swallow.

Do not get in eyes.

Wash skin thoroughly after handling.

Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure assessment.

Keep container tightly closed.

Minimize dust generation and accumulation.

Keep container closed when not in use.

Keep away from heat and sources of ignition.

Take precautionary measures against static discharges.

Take care to prevent spills, waste and minimize release to the environment.

Avoidance of contact:

Oxidizing agents

Hygiene measures:

If exposure to chemical is likely during typical use, provide eye flushing systems and safety showers close to the working place.

When using do not eat, drink or smoke.

Wash contaminated clothing before re-use.

The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the use of administrative controls.

Storage

Conditions for safe storage:

Keep in properly labelled containers.

Keep tightly closed.

Store in accordance with the particular national regulations.

Materials to avoid:

Do not store with the following product types:

Strong oxidizing agents

Packaging material:

Unsuitable material: None known.

8. EXPOSURE CONTROLS/PERSONAL PROTECTION

Threshold limit value and permissible exposure limits for each component in the work environment

<table>
<thead>
<tr>
<th>Components</th>
<th>CAS-No.</th>
<th>Value type (Form of exposure)</th>
<th>Control parameters / Permissible concentration</th>
<th>Basis</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
SAFETY DATA SHEET

Ertugliflozin (< 5%) / Sitagliptin Formulation

<table>
<thead>
<tr>
<th>Ingredient</th>
<th>CAS Number</th>
<th>TWA</th>
<th>Limit Type</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sitagliptin</td>
<td>654671-77-9</td>
<td>TWA 0.5 mg/m³ (OEB 2)</td>
<td>Internal</td>
</tr>
<tr>
<td>Cellulose</td>
<td>9004-34-6</td>
<td>TWA 10 mg/m³</td>
<td>ACGIH</td>
</tr>
<tr>
<td>Ertugliflozin</td>
<td>1210344-83-4</td>
<td>TWA 10 µg/m³ (OEB 3)</td>
<td>Internal</td>
</tr>
<tr>
<td>Magnesium stearate</td>
<td>557-04-0</td>
<td>TWA (Inhalable particulate matter) 10 mg/m³</td>
<td>ACGIH</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Wipe limit 100 µg/100 cm²</td>
<td>Internal</td>
</tr>
</tbody>
</table>

Engineering measures:
All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment. Containment technologies suitable for controlling compounds are required to control at source and to prevent migration of the compound to uncontrolled areas (e.g., open-face containment devices). Minimize open handling.

Personal protective equipment

Respiratory protection:
If adequate local exhaust ventilation is not available or exposure assessment demonstrates exposures outside the recommended guidelines, use respiratory protection.
Filter type: Particulates type
Hand protection
Material: Chemical-resistant gloves
Remarks: Consider double gloving.
Eye protection
Consider safety glasses with side shields or goggles. If the work environment or activity involves dusty conditions, mists or aerosols, wear the appropriate goggles. Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or aerosols.

Skin and body protection:
Work uniform or laboratory coat. Additional body garments should be used based upon the task being performed (e.g., sleevelets, apron, gauntlets, disposable suits) to avoid exposed skin surfaces. Use appropriate degowning techniques to remove potentially contaminated clothing.

9. PHYSICAL AND CHEMICAL PROPERTIES

Physical state: powder
Colour: No data available
Odour: No data available
Odour Threshold: No data available
Melting point/freezing point: No data available

Boiling point, initial boiling point and boiling range: No data available

Flammability (solid, gas): May form explosive dust-air mixture during processing, handling or other means.

Flammability (liquids): No data available

Lower explosion limit and upper explosion limit / flammability limit
Upper explosion limit / Upper flammability limit: No data available

Lower explosion limit / Lower flammability limit: No data available

Flash point: Not applicable

Decomposition temperature: No data available

pH: No data available

Evaporation rate: Not applicable

Auto-ignition temperature: No data available

Viscosity
Viscosity, kinematic: Not applicable

Solubility(ies)
Water solubility: No data available

Partition coefficient: n-octanol/water: Not applicable

Vapour pressure: Not applicable

Density and / or relative density
Relative density: No data available

Density: No data available

Relative vapour density: Not applicable

Explosive properties: Not explosive

Oxidizing properties: The substance or mixture is not classified as oxidizing.

Molecular weight: No data available

Particle characteristics
Particle size: No data available
10. STABILITY AND REACTIVITY

Reactivity: Not classified as a reactivity hazard.
Chemical stability: Stable under normal conditions.
Possibility of hazardous reactions:
May form explosive dust-air mixture during processing, handling or other means.
Can react with strong oxidizing agents.

Conditions to avoid:
Heat, flames and sparks.
Avoid dust formation.

Incompatible materials:
Oxidizing agents

Hazardous decomposition products:
No hazardous decomposition products are known.

11. TOXICOLOGICAL INFORMATION

Information on likely routes of exposure:
Inhalation
Skin contact
Ingestion
Eye contact

Acute toxicity
Not classified based on available information.

Product:
Acute oral toxicity: Acute toxicity estimate: > 2,000 mg/kg
Method: Calculation method

Components:
Sitagliptin:
Acute oral toxicity: LD50 (Rat): > 3,000 mg/kg
LD50 (Mouse): 3,000 mg/kg

Cellulose:
Acute oral toxicity: LD50 (Rat): > 5,000 mg/kg
Acute inhalation toxicity: LC50 (Rat): > 5.8 mg/l
Exposure time: 4 h
Test atmosphere: dust/mist

Acute dermal toxicity: LD50 (Rabbit): > 2,000 mg/kg

Ertugliflozin:
Acute oral toxicity: LD50 (Rat): 500 mg/kg
Acute inhalation toxicity: Remarks: No data available
Acute dermal toxicity: Remarks: No data available
Magnesium stearate:

Acute oral toxicity:
LD50 (Rat): > 2,000 mg/kg
Method: OECD Test Guideline 423
Assessment: The substance or mixture has no acute oral toxicity
Remarks: Based on data from similar materials

Acute dermal toxicity:
LD50 (Rabbit): > 2,000 mg/kg
Remarks: Based on data from similar materials

Skin corrosion/irritation
Causes skin irritation.

Components:

Sitagliptin:
Species: Rabbit
Method: Draize Test
Result: No skin irritation

Ertugliflozin:
Result: Corrosive

Magnesium stearate:
Species: Rabbit
Result: No skin irritation
Remarks: Based on data from similar materials

Serious eye damage/eye irritation
Causes serious eye damage.

Components:

Sitagliptin:
Species: Rabbit
Result: Irritating to eyes.
Method: Draize Test

Ertugliflozin:
Result: Severe irritation

Magnesium stearate:
Species: Rabbit
Result: No eye irritation
Remarks: Based on data from similar materials

Respiratory or skin sensitisation
Skin sensitisation
Not classified based on available information.
Respiratory sensitisation
Not classified based on available information.

Components:

Sitagliptin:
Test Type: Local lymph node assay (LLNA)
Species: Mouse
Method: OECD Test Guideline 429
Result: Not a skin sensitizer.

Ertugliflozin:
Test Type: Local lymph node assay (LLNA)
Result: Not a skin sensitizer.

Magnesium stearate:
Test Type: Maximisation Test
Exposure routes: Skin contact
Species: Guinea pig
Method: OECD Test Guideline 406
Result: negative
Remarks: Based on data from similar materials

Germ cell mutagenicity
Not classified based on available information.

Components:

Sitagliptin:
Genotoxicity in vitro: Test Type: Ames test
Result: negative

Test Type: Chromosome aberration test in vitro
Test system: Chinese hamster ovary cells
Result: negative

Test Type: DNA damage and repair, unscheduled DNA synthesis in mammalian cells (in vitro)
Test system: rat hepatocytes
Result: negative

Genotoxicity in vivo: Test Type: Micronucleus test
Species: Mouse
Application Route: Oral
Result: negative

Cellulose:
Genotoxicity in vitro: Test Type: Bacterial reverse mutation assay (AMES)
Result: negative

Test Type: In vitro mammalian cell gene mutation test
Result: negative
Genotoxicity in vivo:
- Test Type: Mammalian erythrocyte micronucleus test (in vivo cytogenetic assay)
  - Species: Mouse
  - Application Route: Ingestion
  - Result: negative

Ertugliflozin:
- Genotoxicity in vitro:
  - Test Type: Bacterial reverse mutation assay (AMES)
    - Result: negative
  - Test Type: Chromosome aberration test in vitro
    - Result: negative

- Genotoxicity in vivo:
  - Test Type: Mammalian erythrocyte micronucleus test (in vivo cytogenetic assay)
    - Species: Rat
    - Result: negative

Magnesium stearate:
- Genotoxicity in vitro:
  - Test Type: In vitro mammalian cell gene mutation test
    - Result: negative
    - Remarks: Based on data from similar materials
  - Test Type: Chromosome aberration test in vitro
    - Method: OECD Test Guideline 473
    - Result: negative
    - Remarks: Based on data from similar materials
  - Test Type: Bacterial reverse mutation assay (AMES)
    - Result: negative
    - Remarks: Based on data from similar materials

Carcinogenicity
Not classified based on available information.

Components:

Sitagliptin:
- Species: Mouse
- Application Route: Oral
- Exposure time: 2 Years
- Result: negative
- Species: Rat
- Application Route: oral (drinking water)
- Exposure time: 2 Years
- Result: positive
- Target Organs: Liver
- Remarks: Significant toxicity observed in testing

- Carcinogenicity - Assessment: Weight of evidence does not support classification as a carcinogen
SAFETY DATA SHEET

Ertugliflozin (< 5%) / Sitagliptin Formulation

Version 2.1  Revision Date: 2020/09/28  SDS Number: 2400317-00007  Date of last issue: 2020/03/23  Date of first issue: 2018/02/01

Cellulose:
Species: Rat  Application Route: Ingestion  Exposure time: 72 weeks  Result: negative

Ertugliflozin:
Species: Mouse  Application Route: Oral  Exposure time: 2 Years  Result: negative

Species: Rat  Application Route: Oral  Exposure time: 2 Years  Result: negative

Carcinogenicity - Assessment: Weight of evidence does not support classification as a carcinogen

Reproductive toxicity
Not classified based on available information.

Components:

Sitagliptin:
Effects on fertility:
Species: Rat  Application Route: Oral  Fertility: NOAEL Parent: 1,000 mg/kg body weight  Result: Animal testing did not show any effects on fertility.

Effects on foetal development:
Species: Rat  Application Route: Oral  Teratogenicity: LOAEL: 250 mg/kg body weight  Result: Embryotoxic effects and adverse effects on the offspring were detected. No teratogenic effects

Test Type: Embryo-foetal development  Species: Rabbit  Teratogenicity: NOAEL: 125 mg/kg body weight  Result: No teratogenic effects

Cellulose:
Effects on fertility:
Species: Rat  Application Route: Ingestion  Result: negative

Effects on foetal development:
Species: Rat  Application Route: Ingestion
**Ertugliflozin (< 5%) / Sitagliptin Formulation**

**SAFETY DATA SHEET**

Version 2.1  
Revision Date: 2020/09/28  
SDS Number: 2400317-00007  
Date of last issue: 2020/03/23  
Date of first issue: 2018/02/01

---

**Ertugliflozin:**

**Effects on fertility**

- **Test Type:** Fertility/early embryonic development  
- **Species:** Rat  
- **Application Route:** Oral  
- **Fertility:** NOAEL: 250 mg/kg body weight  
- **Remarks:** Maternal toxicity observed. No significant adverse effects were reported

- **Test Type:** Fertility/early embryonic development  
- **Species:** Rabbit  
- **Application Route:** Oral  
- **Fertility:** NOAEL: 200 mg/kg body weight  
- **Remarks:** No significant adverse effects were reported

**Effects on foetal development**

- **Test Type:** Embryo-foetal development  
- **Species:** Rat  
- **Application Route:** Oral  
- **Developmental Toxicity:** NOAEL: 50 mg/kg body weight  
- **Remarks:** Adverse developmental effects were observed

- **Test Type:** Embryo-foetal development  
- **Species:** Rabbit  
- **Application Route:** Oral  
- **Developmental Toxicity:** NOAEL: 250 mg/kg body weight  
- **Remarks:** No significant adverse effects were reported

**Magnesium stearate:**

**Effects on fertility**

- **Test Type:** Combined repeated dose toxicity study with the reproduction/developmental toxicity screening test  
- **Species:** Rat  
- **Application Route:** Ingestion  
- **Method:** OECD Test Guideline 422  
- **Result:** negative  
- **Remarks:** Based on data from similar materials

**Effects on foetal development**

- **Test Type:** Embryo-foetal development  
- **Species:** Rat  
- **Application Route:** Ingestion  
- **Result:** negative  
- **Remarks:** Based on data from similar materials

---

**STOT - single exposure**

Not classified based on available information.

**STOT - repeated exposure**

Not classified based on available information.

---

**Components:**

**Ertugliflozin:**

**Exposure routes:** Oral
Target Organs: Kidney, Stomach, Prostate
Assessment: May cause damage to organs through prolonged or repeated exposure.

**Repeated dose toxicity**

**Components:**

**Sitagliptin:**

<table>
<thead>
<tr>
<th>Species</th>
<th>Mouse</th>
</tr>
</thead>
<tbody>
<tr>
<td>NOAEL</td>
<td>500 mg/kg</td>
</tr>
<tr>
<td>LOAEL</td>
<td>1,000 mg/kg</td>
</tr>
<tr>
<td>Application Route</td>
<td>Oral</td>
</tr>
<tr>
<td>Exposure time</td>
<td>&gt; 2 yr</td>
</tr>
<tr>
<td>Target Organs</td>
<td>Kidney</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Species</th>
<th>Rat</th>
</tr>
</thead>
<tbody>
<tr>
<td>NOAEL</td>
<td>500 mg/kg</td>
</tr>
<tr>
<td>LOAEL</td>
<td>1,000 mg/kg</td>
</tr>
<tr>
<td>Application Route</td>
<td>Oral</td>
</tr>
<tr>
<td>Exposure time</td>
<td>14 Weeks</td>
</tr>
<tr>
<td>Target Organs</td>
<td>Liver, Kidney, Heart, Teeth</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Species</th>
<th>Dog</th>
</tr>
</thead>
<tbody>
<tr>
<td>NOAEL</td>
<td>10 mg/kg</td>
</tr>
<tr>
<td>LOAEL</td>
<td>50 mg/kg</td>
</tr>
<tr>
<td>Application Route</td>
<td>Oral</td>
</tr>
<tr>
<td>Exposure time</td>
<td>53 Weeks</td>
</tr>
<tr>
<td>Target Organs</td>
<td>Central nervous system</td>
</tr>
<tr>
<td>Symptoms</td>
<td>Loss of balance</td>
</tr>
<tr>
<td>Remarks</td>
<td>The mechanism or mode of action may not be relevant in humans.</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Species</th>
<th>Dog</th>
</tr>
</thead>
<tbody>
<tr>
<td>NOAEL</td>
<td>2 mg/kg</td>
</tr>
<tr>
<td>LOAEL</td>
<td>10 mg/kg</td>
</tr>
<tr>
<td>Application Route</td>
<td>Oral</td>
</tr>
<tr>
<td>Exposure time</td>
<td>27 Weeks</td>
</tr>
<tr>
<td>Target Organs</td>
<td>Skeletal muscle, Central nervous system</td>
</tr>
<tr>
<td>Symptoms</td>
<td>Loss of balance</td>
</tr>
<tr>
<td>Remarks</td>
<td>The mechanism or mode of action may not be relevant in humans.</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Species</th>
<th>Monkey</th>
</tr>
</thead>
<tbody>
<tr>
<td>NOAEL</td>
<td>100 mg/kg</td>
</tr>
<tr>
<td>Application Route</td>
<td>Oral</td>
</tr>
<tr>
<td>Exposure time</td>
<td>14 Weeks</td>
</tr>
<tr>
<td>Remarks</td>
<td>No significant adverse effects were reported</td>
</tr>
</tbody>
</table>

**Cellulose:**

<table>
<thead>
<tr>
<th>Species</th>
<th>Rat</th>
</tr>
</thead>
<tbody>
<tr>
<td>NOAEL</td>
<td>&gt;= 9,000 mg/kg</td>
</tr>
<tr>
<td>Application Route</td>
<td>Ingestion</td>
</tr>
<tr>
<td>Exposure time</td>
<td>90 Days</td>
</tr>
</tbody>
</table>
**SAFETY DATA SHEET**

**Ertugliflozin (< 5%) / Sitagliptin Formulation**

**Version** 2.1  **Revision Date:** 2020/09/28  **SDS Number:** 2400317-00007  **Date of last issue:** 2020/03/23  **Date of first issue:** 2018/02/01

---

### Ertugliflozin:
- **Species:** Rat
- **LOAEL:** 500 mg/kg
- **Application Route:** Oral
- **Exposure time:** 30 d

Species: Rat  
LOAEL: 250 mg/kg  
Application Route: Oral  
Exposure time: 30 d  
Target Organs: Kidney

Species: Rat  
LOAEL: 25 mg/kg  
Application Route: Oral  
Exposure time: 180 d  
Target Organs: Kidney, Bone, Stomach

Species: Rat  
LOAEL: 25 mg/kg  
Application Route: Oral  
Exposure time: 90 d  
Target Organs: Kidney, Gastrointestinal tract, Prostate

Species: Dog  
NOAEL: 150 mg/kg  
Application Route: Oral  
Exposure time: 270 d  
Remarks: No significant adverse effects were reported

Species: Mouse  
NOAEL: 100 mg/kg  
Application Route: Oral  
Exposure time: 90 d  
Remarks: No significant adverse effects were reported

Species: Mouse  
NOAEL: 100 mg/kg  
Application Route: Oral  
Exposure time: 28 d  
Target Organs: Bone  
Remarks: No significant adverse effects were reported

### Magnesium stearate:
- **Species:** Rat  
- **NOAEL:** > 100 mg/kg  
- **Application Route:** Ingestion  
- **Exposure time:** 90 Days  
- **Remarks:** Based on data from similar materials

### Aspiration toxicity
Not classified based on available information.
Experience with human exposure

**Components:**

**Sitagliptin:**
- **Inhalation**
  - Symptoms: upper respiratory tract infection, pharyngitis, Headache
- **Ingestion**
  - Symptoms: upper respiratory tract infection, nasopharyngitis, Headache, Nausea, Abdominal pain, Diarrhoea

**Ertugliflozin:**
- **Ingestion**
  - Symptoms: The most common side effects are:, Headache, constipation, Diarrhoea, Nausea, urinary tract infection, muscle pain, upper respiratory tract infection

12. ECOLOGICAL INFORMATION

**Ecotoxicity**

**Components:**

**Sitagliptin:**
- **Toxicity to fish**
  - LC50 (Pimephales promelas (fathead minnow)): > 100 mg/l
  - Exposure time: 96 h
  - Method: OECD Test Guideline 203
- **Toxicity to daphnia and other aquatic invertebrates**
  - EC50 (Daphnia magna (Water flea)): 60 mg/l
  - Exposure time: 48 h
  - Method: OECD Test Guideline 202
- **Toxicity to algae/aquatic plants**
  - EC50 (Pseudokirchneriella subcapitata (green algae)): > 39 mg/l
  - Exposure time: 96 h
  - Method: OECD Test Guideline 201
  - NOEC (Pseudokirchneriella subcapitata (green algae)): 2.2 mg/l
  - Exposure time: 96 h
  - Method: OECD Test Guideline 201
- **Toxicity to fish (Chronic toxicity)**
  - NOEC (Pimephales promelas (fathead minnow)): 9.2 mg/l
  - Exposure time: 33 d
  - Method: OECD Test Guideline 210
- **Toxicity to daphnia and other aquatic invertebrates (Chronic toxicity)**
  - NOEC (Daphnia magna (Water flea)): 9.8 mg/l
  - Exposure time: 21 d
  - Method: OECD Test Guideline 211
- **Toxicity to microorganisms**
  - EC50: > 150 mg/l
  - Exposure time: 3 h
  - Test Type: Respiration inhibition
  - Method: OECD Test Guideline 209
NOEC: 150 mg/l
Exposure time: 3 h
Test Type: Respiration inhibition

Cellulose:
Toxicity to fish: LC50 (Oryzias latipes (Japanese medaka)): > 100 mg/l
Exposure time: 48 h
Remarks: Based on data from similar materials

Ertugliflozin:
Toxicity to algae/aquatic plants: EC50 (Pseudokirchneriella subcapitata (green algae)): 77 mg/l
Exposure time: 72 h
Method: OECD Test Guideline 201

NOEC (Pseudokirchneriella subcapitata (green algae)): 50 mg/l
Exposure time: 72 h
Method: OECD Test Guideline 201

Toxicity to fish (Chronic toxicity): NOEC (Pimephales promelas (fathead minnow)): 1 mg/l
Exposure time: 32 d
Method: OECD Test Guideline 210
Remarks: No toxicity at the limit of solubility

Toxicity to daphnia and other aquatic invertebrates (Chronic toxicity): NOEC (Daphnia magna (Water flea)): 2.14 mg/l
Exposure time: 21 d
Method: OECD Test Guideline 211
Remarks: No toxicity at the limit of solubility

Toxicity to microorganisms: EC50: > 1,000 mg/l
Exposure time: 3 h
Test Type: Respiration inhibition
Method: OECD Test Guideline 209

NOEC: 1,000 mg/l
Exposure time: 3 h
Test Type: Respiration inhibition
Method: OECD Test Guideline 209

Magnesium stearate:
Toxicity to fish: LC50 (Leuciscus idus (Golden orfe)): > 100 mg/l
Exposure time: 48 h
Method: DIN 38412
Remarks: Based on data from similar materials

Toxicity to daphnia and other aquatic invertebrates: EL50 (Daphnia magna (Water flea)): > 1 mg/l
Exposure time: 47 h
Test substance: Water Accommodated Fraction
Remarks: Based on data from similar materials
No toxicity at the limit of solubility
**Toxicity to algae/aquatic plants**

<table>
<thead>
<tr>
<th>Test substance:</th>
<th>Water Accommodated Fraction</th>
</tr>
</thead>
<tbody>
<tr>
<td>Method:</td>
<td>OECD Test Guideline 201</td>
</tr>
<tr>
<td>Remarks:</td>
<td>Based on data from similar materials</td>
</tr>
<tr>
<td>NOELR (Pseudokirchneriella subcapitata):</td>
<td>&gt; 1 mg/l</td>
</tr>
<tr>
<td>Exposure time:</td>
<td>72 h</td>
</tr>
<tr>
<td>Test substance:</td>
<td>Water Accommodated Fraction</td>
</tr>
<tr>
<td>Method:</td>
<td>OECD Test Guideline 201</td>
</tr>
<tr>
<td>Remarks:</td>
<td>Based on data from similar materials</td>
</tr>
</tbody>
</table>

**Toxicity to microorganisms**

<table>
<thead>
<tr>
<th>Test substance:</th>
<th>Water Accommodated Fraction</th>
</tr>
</thead>
<tbody>
<tr>
<td>Method:</td>
<td>OECD Test Guideline 201</td>
</tr>
<tr>
<td>Remarks:</td>
<td>Based on data from similar materials</td>
</tr>
<tr>
<td>EC10 (Pseudomonas putida):</td>
<td>&gt; 100 mg/l</td>
</tr>
<tr>
<td>Exposure time:</td>
<td>16 h</td>
</tr>
</tbody>
</table>

**Persistence and degradability**

**Components:**

**Sitagliptin:**

Biodegradability: Result: not rapidly degradable
Biodegradation: 39.7 %
Exposure time: 28 d
Method: OECD Test Guideline 314

Stability in water: Hydrolysis: 50 % (401 d)
Method: OECD Test Guideline 111

**Cellulose:**

Biodegradability: Result: Readily biodegradable.

**Ertugliflozin:**

Biodegradability: Result: Not readily biodegradable.
Biodegradation: 40.8 %
Exposure time: 28 d

**Magnesium stearate:**

Biodegradability: Result: Not biodegradable
Remarks: Based on data from similar materials

**Bioaccumulative potential**

**Components:**

**Sitagliptin:**

Partition coefficient: n-octanol/water: log Pow: -0.03
SAFETY DATA SHEET

Ertugliflozin (< 5%) / Sitagliptin Formulation

Version 2.1  Revision Date: 2020/09/28  SDS Number: 2400317-00007  Date of last issue: 2020/03/23  Date of first issue: 2018/02/01

Ertugliflozin:
Partition coefficient: n-octanol/water : log Pow: 2.47

Magnesium stearate:
Partition coefficient: n-octanol/water : log Pow: > 4

Mobility in soil

Components:

Sitagliptin:
Distribution among environmental compartments : log Koc: 4.37

Ertugliflozin:
Distribution among environmental compartments : log Koc: 2.88

Hazardous to the ozone layer
Not applicable

Other adverse effects
No data available

13. DISPOSAL CONSIDERATIONS

Disposal methods
Waste from residues : Dispose of in accordance with local regulations.
Contaminated packaging : Empty containers should be taken to an approved waste handling site for recycling or disposal. If not otherwise specified: Dispose of as unused product.

14. TRANSPORT INFORMATION

International Regulations

UNRTDG
Not regulated as a dangerous good

IATA-DGR
Not regulated as a dangerous good

IMDG-Code
Not regulated as a dangerous good

Transport in bulk according to Annex II of MARPOL 73/78 and the IBC Code
Not applicable for product as supplied.

National Regulations
Refer to section 15 for specific national regulation.
15. REGULATORY INFORMATION

Related Regulations

Fire Service Law
Not applicable to dangerous materials / designated flammables.

Chemical Substance Control Law
Not applicable for Specified Chemical Substance, Monitoring Chemical Substance and Priority Assessment Chemical Substance.

Industrial Safety and Health Law
Harmful Substances Prohibited from Manufacture
Not applicable

Harmful Substances Required Permission for Manufacture
Not applicable

Substances Prevented From Impairment of Health
Not applicable

Circular concerning Information on Chemicals having Mutagenicity - Annex 2: Information on Existing Chemicals having Mutagenicity
Not applicable

Circular concerning Information on Chemicals having Mutagenicity - Annex 1: Information on Notified Substances having Mutagenicity
Not applicable

Substances Subject to be Notified Names
Article 57-2 (Enforcement Order Table 9)

<table>
<thead>
<tr>
<th>Chemical name</th>
<th>Number</th>
<th>Concentration (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Magnesium stearate</td>
<td>327</td>
<td>&gt;=1 - &lt;10</td>
</tr>
</tbody>
</table>

Substances Subject to be Indicated Names
Article 57 (Enforcement Order Article 18)

<table>
<thead>
<tr>
<th>Chemical name</th>
<th>Number</th>
</tr>
</thead>
<tbody>
<tr>
<td>Magnesium stearate</td>
<td>327</td>
</tr>
</tbody>
</table>

Ordinance on Prevention of Hazards Due to Specified Chemical Substances
Not applicable

Ordinance on Prevention of Lead Poisoning
Not applicable

Ordinance on Prevention of Tetraalkyl Lead Poisoning
Not applicable

Ordinance on Prevention of Organic Solvent Poisoning
Not applicable

Enforcement Order of the Industrial Safety and Health Law - Attached table 1 (Dangerous Substances)
Not applicable
Poisonous and Deleterious Substances Control Law
Not applicable

Act on Confirmation, etc. of Release Amounts of Specific Chemical Substances in the Environment and Promotion of Improvements to the Management Thereof
Not applicable

High Pressure Gas Safety Act
Not applicable

Explosive Control Law
Not applicable

Vessel Safety Law
Not regulated as a dangerous good

Aviation Law
Not regulated as a dangerous good

Marine Pollution and Sea Disaster Prevention etc Law
Bulk transportation : Not classified as noxious liquid substance
Pack transportation : Not classified as marine pollutant

Narcotics and Psychotropics Control Act
Narcotic or Psychotropic Raw Material (Export / Import Permission)
Not applicable

Specific Narcotic or Psychotropic Raw Material (Export / Import permission)
Not applicable

Waste Disposal and Public Cleansing Law
Industrial waste

The components of this product are reported in the following inventories:
AICS : not determined
DSL : not determined
IECSC : not determined

16. OTHER INFORMATION

Further information

Date format : yyyy/mm/dd

Full text of other abbreviations
ACGIH : USA. ACGIH Threshold Limit Values (TLV)
ACGIH / TWA : 8-hour, time-weighted average
The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.